Your browser doesn't support javascript.
loading
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.
Chan, Joseph M; Quintanal-Villalonga, Álvaro; Gao, Vianne Ran; Xie, Yubin; Allaj, Viola; Chaudhary, Ojasvi; Masilionis, Ignas; Egger, Jacklynn; Chow, Andrew; Walle, Thomas; Mattar, Marissa; Yarlagadda, Dig V K; Wang, James L; Uddin, Fathema; Offin, Michael; Ciampricotti, Metamia; Qeriqi, Besnik; Bahr, Amber; de Stanchina, Elisa; Bhanot, Umesh K; Lai, W Victoria; Bott, Matthew J; Jones, David R; Ruiz, Arvin; Baine, Marina K; Li, Yanyun; Rekhtman, Natasha; Poirier, John T; Nawy, Tal; Sen, Triparna; Mazutis, Linas; Hollmann, Travis J; Pe'er, Dana; Rudin, Charles M.
Afiliação
  • Chan JM; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
  • Quintanal-Villalonga Á; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Gao VR; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; Weill Cornell Medical College, New York, NY 10065, USA.
  • Xie Y; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; Weill Cornell Medical College, New York, NY 10065, USA.
  • Allaj V; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Chaudhary O; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
  • Masilionis I; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
  • Egger J; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Chow A; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Walle T; Department of Medical Oncology; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Clinical Cooperation Unit Virotherapy; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Mattar M; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Yarlagadda DVK; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
  • Wang JL; Department of Computer Science, Columbia University, New York, NY 10027, USA.
  • Uddin F; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Offin M; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Ciampricotti M; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Qeriqi B; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Bahr A; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • de Stanchina E; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Bhanot UK; Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Lai WV; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Bott MJ; Thoracic Service, Department of Surgery, Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Jones DR; Thoracic Service, Department of Surgery, Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Ruiz A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Baine MK; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Li Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Rekhtman N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Poirier JT; Perlmutter Cancer Center, New York University Langone Health, New York, NY 10065, USA.
  • Nawy T; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
  • Sen T; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA.
  • Mazutis L; Institute of Biotechnology, Vilnius University, Vilnius, Lithuania.
  • Hollmann TJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Pe'er D; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: peerster@gmail.com.
  • Rudin CM; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: rudinc@mskc
Cancer Cell ; 39(11): 1479-1496.e18, 2021 11 08.
Article em En | MEDLINE | ID: mdl-34653364
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define the heterogeneity of tumors and their associated microenvironments across subtypes, we sequenced 155,098 transcriptomes from 21 human biospecimens, including 54,523 SCLC transcriptomes. We observe greater tumor diversity in SCLC than lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes. We discover a PLCG2-high SCLC phenotype with stem-like, pro-metastatic features that recurs across subtypes and predicts worse overall survival. SCLC exhibits greater immune sequestration and less immune infiltration than lung adenocarcinoma, and SCLC-N shows less immune infiltrate and greater T cell dysfunction than SCLC-A. We identify a profibrotic, immunosuppressive monocyte/macrophage population in SCLC tumors that is particularly associated with the recurrent, PLCG2-high subpopulation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Perfilação da Expressão Gênica / Fosfolipase C gama / Carcinoma de Pequenas Células do Pulmão / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Perfilação da Expressão Gênica / Fosfolipase C gama / Carcinoma de Pequenas Células do Pulmão / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article